brazilian
health
regulatory
agency
anvisa
authorizes
sorrento
therapeutics
large
phase
clinical
trial
abivertinib
mild
moderate
severe
patients
phase
clinical
trials
abivertinib
cleared
proceed
brazil
studies
complementary
address
dose
duration
disease
stage
rapid
enrollment
expected
geographies
san
diego
globe
newswire
sorrento
therapeutics
nasdaq
srne
sorrento
today
announced
receipt
clearance
brazilian
regulatory
agency
anvisa
proceed
phase
clinical
trial
abivertinib
mild
moderate
severe
patients
brazil
study
phase
randomized
study
safety
efficacy
abivertinib
maleate
subjects
hospitalized
due
particularly
looking
potential
clinical
benefits
drug
associated
broad
ability
mode
action
reduce
inflammatory
cytokine
storm
dose
tested
phase
trial
trial
protocol
brazil
includes
patients
earlier
stages
disease
drug
administration
regimen
days
versus
days
advanced
patients
brazilian
study
expected
rapidly
enroll
patients
rapid
projected
enrollment
pace
made
possible
recent
partnership
established
sorrento
leading
local
clinical
research
organization
synova
health
access
high
quality
medical
centers
throughout
country
broad
clinical
development
strategic
alignment
sorrento
local
medical
systems
including
city
rio
de
janeiro
also
help
accelerate
site
initiation
access
potential
patients
additional
sorrento
studies
currently
evaluated
anvisa
br
protocol
design
protocol
design
mild
moderate
severe
patients
severe
patients
hospitalized
patient
icu
randomized
abivertinib
placebo
randomized
abivertinib
placebo
mg
qd
x
days
mg
qd
x
days
duration
days
duration
days
primary
endpoint
discharged
hospital
week
primary
endpoint
alive
free
respiratory
failure
week
satisfied
progress
made
brazil
far
stated
henry
ji
chairman
ceo
sorrento
therapeutics
targeting
geographies
currently
impacted
able
implement
synergistic
program
answer
questions
safety
efficacy
drug
candidates
helping
patients
potentially
accelerating
enrollment
timelines
reducing
overall
cost
opening
collaboration
opportunities
local
study
referenced
anvisa
brazilian
authority
process
nÂº
reference
brazilian
clinical
study
details
found
https
show
sorrento
therapeutics
sorrento
clinical
stage
biopharmaceutical
company
developing
new
therapies
treat
cancers
sorrento
multimodal
multipronged
approach
fighting
cancer
made
possible
extensive
platforms
including
key
assets
fully
human
antibodies
library
clinical
stage
therapies
conjugates
adcs
clinical
stage
oncolytic
virus
sorrento
also
developing
potential
antiviral
therapies
vaccines
coronaviruses
including
diagnostic
test
solutions
including
sorrento
commitment
therapies
patients
also
demonstrated
effort
advance
agonist
pain
management
small
molecule
resiniferatoxin
rtx
lidocaine
topical
system
treatment
neuralgia
rtx
completed
phase
trial
intractable
pain
associated
cancer
phase
trial
osteoarthritis
patients
approved
fda
february
information
visit
statements
press
release
statements
made
presentation
meeting
contain
statements
related
sorrento
therapeutics
safe
harbor
provisions
section
private
securities
litigation
reform
act
subject
risks
uncertainties
could
cause
actual
results
differ
materially
projected
statements
include
statements
regarding
abivertinib
including
safety
tolerability
demonstrated
efficacy
thereof
potential
ability
abivertinib
reduce
inflammatory
cytokine
activity
expected
rapid
enrollment
clinical
trials
brazil
protocol
design
brazilian
clinical
trials
synergistic
potential
brazil
clinical
trials
ability
synergistic
program
potentially
accelerate
enrollment
timelines
reduce
overall
cost
create
collaboration
opportunities
local
companies
risks
uncertainties
could
cause
actual
results
differ
materially
adversely
expressed
statements
include
limited
risks
related
sorrento
subsidiaries
affiliates
partners
technologies
prospects
collaborations
partners
including
limited
clinical
development
risks
including
risks
progress
timing
cost
results
clinical
trials
product
development
programs
risk
difficulties
delays
obtaining
regulatory
approvals
risks
clinical
study
results
may
meet
endpoints
clinical
study
data
generated
studies
may
support
regulatory
submission
approval
risks
prior
test
study
trial
results
may
replicated
future
studies
trials
risks
manufacturing
supplying
drug
product
risks
related
leveraging
expertise
employees
subsidiaries
affiliates
partners
assist
company
execution
therapeutic
product
candidates
strategies
risks
related
global
impact
risks
described
sorrento
recent
periodic
reports
filed
securities
exchange
commission
including
sorrento
annual
report
form
year
ended
december
subsequent
quarterly
reports
form
filed
securities
exchange
commission
including
risk
factors
set
forth
filings
investors
cautioned
place
undue
reliance
statements
speak
date
release
undertake
obligation
update
statement
press
release
except
required
law
contact
alexis
nahama
dvm
svp
corporate
development
email
mediarelations
sorrento
logo
registered
trademarks
sorrento
therapeutics
trademarks
sorrento
therapeutics
trademark
owned
scilex
pharmaceuticals
trademarks
property
respective
owners
sorrento
therapeutics
rights
reserved
